Temat: "Pyridines" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.
Autorzy:: She X; Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Yin D; Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Guo Q; Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Tang Y; Department of Pharmacy, School of Pharmacy, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Wang S; Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China. .
Wang X; Central Laboratory, Shanxi Hospital of Integrated Traditional Chinese and Western Medicine, Taiyuan, Shanxi, People's Republic of China. .; Key Laboratory of Research and Development of Traditional Chinese Medicine Preparations, Taiyuan, Shanxi, People's Republic of China. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Mar 07; Vol. 14 (1), pp. 5592. Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Anilides*
Carcinoma, Renal Cell*/drug therapy
Indazoles*
Kidney Neoplasms*/pathology
Phenylurea Compounds*
Pyridines*
Pyrimidines*
Quinolines*
Sulfonamides*
Aged ; Humans ; Male ; Axitinib/therapeutic use ; Bayes Theorem ; Electrolytes ; Pharmacovigilance ; Retrospective Studies ; Sorafenib/adverse effects ; Sunitinib/adverse effects ; United States ; United States Food and Drug Administration ; Female ; Middle Aged

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: A study protocol for an open-label, single-arm, single-center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma.
Autorzy:: Huang H; Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Zhang H; Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Cao B; Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2024 Feb; Vol. 15 (5), pp. 427-433. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:: Clinical Trial Protocol; Journal Article
MeSH Terms:: Antineoplastic Agents*/therapeutic use
Sarcoma*/drug therapy
Sarcoma*/pathology
Piperidines*
Pyridines*
Pyrimidines*
Humans ; Phosphatidylinositol 3-Kinases ; Clinical Trials, Phase I as Topic

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRAS -Mutated Lung Adenocarcinoma.
Autorzy:: Lin P; Key Laboratory of Marine Drugs, Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Cheng W; Key Laboratory of Marine Drugs, Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Qi X; Key Laboratory of Marine Drugs, Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Zhang P; Faculty of Information Science and Engineering, Ocean University of China, Qingdao 266003, China.
Xiong J; Faculty of Information Science and Engineering, Ocean University of China, Qingdao 266003, China.
Li J; Key Laboratory of Marine Drugs, Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Jan 26; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 26.
Typ publikacji:: Journal Article
MeSH Terms:: Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
F-Box Proteins*
Piperazines*
Pyridines*
Pyrimidines*
Humans ; Proto-Oncogene Proteins p21(ras) ; Computational Biology ; Biomarkers ; Mutation ; Transcription Factors ; Tumor Microenvironment/genetics ; Neoplasm Proteins

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Glycogen Synthase Kinase-3 Inhibition by CHIR99021 Promotes Alveolar Epithelial Cell Proliferation and Lung Regeneration in the Lipopolysaccharide-Induced Acute Lung Injury Mouse Model.
Autorzy:: Fernandes R; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, 4806-909 Braga, Portugal.
Barbosa-Matos C; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, 4806-909 Braga, Portugal.
Borges-Pereira C; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, 4806-909 Braga, Portugal.
Carvalho ALRT; Department of Internal Medicine, São João Universitary Hospital Center, 4200-319 Porto, Portugal.; Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
Costa S; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, 4806-909 Braga, Portugal.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Jan 20; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 20.
Typ publikacji:: Journal Article
MeSH Terms:: Alveolar Epithelial Cells*
Acute Lung Injury*/chemically induced
Acute Lung Injury*/pathology
Pyridines*
Pyrimidines*
Animals ; Mice ; Lipopolysaccharides/pharmacology ; Glycogen Synthase Kinase 3 ; Lung/pathology ; Cell Proliferation

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Short-term autophagy inhibition by autophinib or SAR405 does not alter the effect of cisplatin on ATP production in prostate cancer cells.
Autorzy:: Kratochvilova M
Stepka P
Raudenska M
Balvan J
Richtera L
Cernei N
Skopalova DS
Zitka O
Filipensky P
Babula P
Masarik M; Pokaż więcej
Źródło:: Bratislavske lekarske listy [Bratisl Lek Listy] 2024; Vol. 124 (2), pp. 84-91.
Typ publikacji:: Journal Article
MeSH Terms:: Cisplatin*/pharmacology
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/pathology
Pyrazoles*
Pyridines*
Pyrimidines*
Pyrimidinones*
Male ; Humans ; Autophagy ; Cell Line, Tumor ; Amino Acids/pharmacology ; Amino Acids/metabolism ; Adenosine Triphosphate/pharmacology ; Arginine

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: 6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation.
Autorzy:: Chaudhary CL; College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.
Lim D; Innovo Therapeutics Inc, Daejeon, Republic of Korea.
Chaudhary P; College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.
Guragain D; College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.
Awasthi BP; College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.
Park HD; Innovo Therapeutics Inc, Daejeon, Republic of Korea.
Kim JA; College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.
Jeong BS; College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.; Pokaż więcej
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 844-856.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Design*
Antineoplastic Agents/*pharmacology
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Pyridines/*pharmacology
Pyrimidines/*pharmacology
Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Carcinoma, Hepatocellular/pathology ; Cell Proliferation/drug effects ; Chickens ; Dose-Response Relationship, Drug ; Humans ; Liver Neoplasms/pathology ; Liver Neoplasms, Experimental/drug therapy ; Liver Neoplasms, Experimental/pathology ; Models, Molecular ; Molecular Structure ; Pyridines/chemical synthesis ; Pyridines/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Structure-Activity Relationship ; Tumor Cells, Cultured

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA-PKcs.
Autorzy:: Djuzenova CS; Department of Radiation Oncology, University Hospital of Würzburg, Josef-Schneider-Strasse 11, 97080, Würzburg, Germany. djuzenova_.
Fischer T; Department of Radiation Oncology, University Hospital of Würzburg, Josef-Schneider-Strasse 11, 97080, Würzburg, Germany.
Katzer A; Department of Radiation Oncology, University Hospital of Würzburg, Josef-Schneider-Strasse 11, 97080, Würzburg, Germany.
Sisario D; Department of Biotechnology and Biophysics, University of Würzburg, Würzburg, Germany.
Korsa T; Department of Biotechnology and Biophysics, University of Würzburg, Würzburg, Germany.
Steussloff G; Department of Radiation Oncology, University Hospital of Würzburg, Josef-Schneider-Strasse 11, 97080, Würzburg, Germany.
Sukhorukov VL; Department of Biotechnology and Biophysics, University of Würzburg, Würzburg, Germany.
Flentje M; Department of Radiation Oncology, University Hospital of Würzburg, Josef-Schneider-Strasse 11, 97080, Würzburg, Germany.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 Nov 11; Vol. 21 (1), pp. 1201. Date of Electronic Publication: 2021 Nov 11.
Typ publikacji:: Journal Article
MeSH Terms:: Brain Neoplasms/*therapy
DNA-Activated Protein Kinase/*deficiency
Furans/*pharmacology
Glioblastoma/*therapy
Pyridines/*pharmacology
Pyrimidines/*pharmacology
Radiation Tolerance/*drug effects
Brain Neoplasms/genetics ; Brain Neoplasms/pathology ; Cell Line, Tumor ; Chemoradiotherapy/methods ; DNA-Activated Protein Kinase/antagonists & inhibitors ; DNA-Activated Protein Kinase/genetics ; DNA-Activated Protein Kinase/metabolism ; Furans/therapeutic use ; Glioblastoma/genetics ; Glioblastoma/pathology ; Humans ; Phosphatidylinositol 3-Kinases/metabolism ; Pyridines/therapeutic use ; Pyrimidines/therapeutic use ; Radiation Tolerance/genetics ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; TOR Serine-Threonine Kinases/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Design, Synthesis and SAR in 2,4,7-Trisubstituted Pyrido[3,2- d ]Pyrimidine Series as Novel PI3K/mTOR Inhibitors.
Autorzy:: Buron F; Institut de Chimie Organique et Analytique, Université d'Orléans, UMR CNRS 7311, rue de Chartres, BP 6759, 45067 Orléans, France.
Rodrigues N; Institut de Chimie Organique et Analytique, Université d'Orléans, UMR CNRS 7311, rue de Chartres, BP 6759, 45067 Orléans, France.
Saurat T; Institut de Chimie Organique et Analytique, Université d'Orléans, UMR CNRS 7311, rue de Chartres, BP 6759, 45067 Orléans, France.; Centre de Biophysique Moléculaire, CNRS Orléans, Rue Charles Sadron, 45071 Orléans, France.
Hiebel MA; Institut de Chimie Organique et Analytique, Université d'Orléans, UMR CNRS 7311, rue de Chartres, BP 6759, 45067 Orléans, France.
Bourg S; Institut de Chimie Organique et Analytique, Université d'Orléans, UMR CNRS 7311, rue de Chartres, BP 6759, 45067 Orléans, France.
Bonnet P; Institut de Chimie Organique et Analytique, Université d'Orléans, UMR CNRS 7311, rue de Chartres, BP 6759, 45067 Orléans, France.
Nehmé R; Institut de Chimie Organique et Analytique, Université d'Orléans, UMR CNRS 7311, rue de Chartres, BP 6759, 45067 Orléans, France.
Morin P; Institut de Chimie Organique et Analytique, Université d'Orléans, UMR CNRS 7311, rue de Chartres, BP 6759, 45067 Orléans, France.
Percina N; Institut de Chimie Organique et Analytique, Université d'Orléans, UMR CNRS 7311, rue de Chartres, BP 6759, 45067 Orléans, France.
Corret J; Centre de Biophysique Moléculaire, CNRS Orléans, Rue Charles Sadron, 45071 Orléans, France.
Vallée B; Centre de Biophysique Moléculaire, CNRS Orléans, Rue Charles Sadron, 45071 Orléans, France.
le Guevel R; Campus de Villejean, ImPACcell, Structure Fédérative de Recherche BIOSIT, Université de Rennes 1, Bat 8, 2 Avenue du Pr. Leon Bernard, CS34317, 35043 Rennes, France.
Jourdan ML; Nutrition Croissance et Métabolisme, N2C, INSERM U1069, CHU Tours, Faculté de Médecine, 10 boulevard Tonnellé, 37032 Tours, France.
Bénédetti H; Centre de Biophysique Moléculaire, CNRS Orléans, Rue Charles Sadron, 45071 Orléans, France.
Routier S; Institut de Chimie Organique et Analytique, Université d'Orléans, UMR CNRS 7311, rue de Chartres, BP 6759, 45067 Orléans, France.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2021 Sep 02; Vol. 26 (17). Date of Electronic Publication: 2021 Sep 02.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Design*
Phosphatidylinositol 3-Kinases/*metabolism
Protein Kinase Inhibitors/*pharmacology
Pyridines/*pharmacology
Pyrimidines/*pharmacology
TOR Serine-Threonine Kinases/*antagonists & inhibitors
Cell Line, Tumor ; Dose-Response Relationship, Drug ; Humans ; Molecular Docking Simulation ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyridines/chemical synthesis ; Pyridines/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Structure-Activity Relationship ; TOR Serine-Threonine Kinases/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor.
Autorzy:: Chan P; Department of Clinical Pharmacology, Genentech, Inc, South San Francisco, California, USA.
Ding HT; Department of Clinical Pharmacology, Genentech, Inc, South San Francisco, California, USA.
Liederer BM; Department of Drug Metabolism & Pharmacokinetics, Genentech, Inc, South San Francisco, California, USA.
Mao J; Department of Drug Metabolism & Pharmacokinetics, Genentech, Inc, South San Francisco, California, USA.
Belloni P; Department of Clinical Sciences, Early Clinical Development, Genentech, Inc, South San Francisco, California, USA.
Chen L; Department of Drug Metabolism & Pharmacokinetics, Genentech, Inc, South San Francisco, California, USA.
Gao SS; Department of Clinical Imaging, Genentech, Inc, South San Francisco, California, USA.
Joseph V; Department of Biomedical Imaging, Genentech, Inc, South San Francisco, California, USA.
Yang X; Department of Biostatistics, Early Clinical Development, Genentech, Inc, South San Francisco, California, USA.
Lin JS; Department of Clinical Sciences, Early Clinical Development, Genentech, Inc, South San Francisco, California, USA.
Mitra MS; Department of Toxicology, Genentech, Inc, South San Francisco, California, USA.
Putnam WS; Department of Clinical Pharmacology, Genentech, Inc, South San Francisco, California, USA.
Quartino A; Department of Clinical Pharmacology, Genentech, Inc, South San Francisco, California, USA.
Bauer RN; Department of Biomarker Development, Early Clinical Development, Genentech, Inc, South San Francisco, California, USA.
Pan L; Department of Clinical Pharmacology, Genentech, Inc, South San Francisco, California, USA.; Pokaż więcej
Źródło:: Clinical and translational science [Clin Transl Sci] 2021 Sep; Vol. 14 (5), pp. 1945-1954. Date of Electronic Publication: 2021 May 31.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Models, Biological*
Pyridines/*pharmacokinetics
Pyrimidines/*pharmacokinetics
Regional Blood Flow/*drug effects
TRPA1 Cation Channel/*antagonists & inhibitors
Administration, Intravenous ; Adult ; Animals ; Biological Availability ; Dogs ; Dose-Response Relationship, Drug ; Drug Evaluation, Preclinical ; Female ; Gastrointestinal Absorption ; Healthy Volunteers ; Humans ; Isothiocyanates/administration & dosage ; Macaca fascicularis ; Male ; Middle Aged ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Rats ; Skin/blood supply ; Translational Research, Biomedical ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Females.
Autorzy:: Landry I; Eisai Inc., Woodcliff Lake, New Jersey, USA.
Aluri J; Eisai Inc., Woodcliff Lake, New Jersey, USA.
Hall N; Eisai Inc., Woodcliff Lake, New Jersey, USA.
Filippov G; Eisai Inc., Woodcliff Lake, New Jersey, USA.
Dayal S; Eisai Ltd., Hatfield, UK.
Moline M; Eisai Inc., Woodcliff Lake, New Jersey, USA.
Reyderman L; Eisai Inc., Woodcliff Lake, New Jersey, USA.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 Sep; Vol. 10 (9), pp. 1089-1098. Date of Electronic Publication: 2021 Jun 09.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Ethinyl Estradiol/*administration & dosage
Norethindrone/*administration & dosage
Pyridines/*administration & dosage
Pyrimidines/*administration & dosage
Adolescent ; Adult ; Area Under Curve ; Contraceptives, Oral, Combined/administration & dosage ; Contraceptives, Oral, Combined/pharmacokinetics ; Contraceptives, Oral, Combined/pharmacology ; Drug Interactions ; Ethinyl Estradiol/pharmacokinetics ; Ethinyl Estradiol/pharmacology ; Female ; Humans ; Norethindrone/pharmacokinetics ; Norethindrone/pharmacology ; Orexin Receptor Antagonists/administration & dosage ; Orexin Receptor Antagonists/pharmacokinetics ; Orexin Receptor Antagonists/pharmacology ; Pyridines/pharmacokinetics ; Pyridines/pharmacology ; Pyrimidines/pharmacokinetics ; Pyrimidines/pharmacology ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
Autorzy:: Landry I; Eisai Inc., Woodcliff Lake, New Jersey, USA.
Aluri J; Eisai Inc., Woodcliff Lake, New Jersey, USA.
Nakai K; Eisai Co., Ltd, Tokyo, Japan.
Hall N; Eisai Inc., Woodcliff Lake, New Jersey, USA.
Miyajima Y; Eisai Co., Ltd, Tokyo, Japan.
Ueno T; Eisai Co., Ltd, Tokyo, Japan.
Dayal S; Eisai Ltd., Hatfield, UK.
Filippov G; Eisai Inc., Woodcliff Lake, New Jersey, USA.
Lalovic B; Eisai Inc., Woodcliff Lake, New Jersey, USA.
Moline M; Eisai Inc., Woodcliff Lake, New Jersey, USA.
Reyderman L; Eisai Inc., Woodcliff Lake, New Jersey, USA.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 Jun; Vol. 10 (6), pp. 681-690. Date of Electronic Publication: 2021 Jan 17.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cytochrome P-450 CYP2B6/*drug effects
Cytochrome P-450 CYP3A/*drug effects
Orexin Receptor Antagonists/*administration & dosage
Pyridines/*administration & dosage
Pyrimidines/*administration & dosage
Adult ; Area Under Curve ; Cytochrome P-450 CYP2B6/metabolism ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Cytochrome P-450 Enzyme Inducers/pharmacology ; Drug Interactions ; Female ; Humans ; Male ; Middle Aged ; Orexin Receptor Antagonists/pharmacokinetics ; Orexin Receptor Antagonists/pharmacology ; Pyridines/pharmacokinetics ; Pyridines/pharmacology ; Pyrimidines/pharmacokinetics ; Pyrimidines/pharmacology ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors.
Autorzy:: Ueno T; Eisai Co. Ltd, Tsukuba, Ibaraki, Japan.
Miyajima Y; Eisai Co. Ltd, Tsukuba, Ibaraki, Japan.
Landry I; Eisai Inc, Woodcliff Lake, New Jersey, USA.
Lalovic B; Eisai Inc, Woodcliff Lake, New Jersey, USA.
Schuck E; Eisai Inc, Woodcliff Lake, New Jersey, USA.; Pokaż więcej
Źródło:: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 May; Vol. 10 (5), pp. 455-466. Date of Electronic Publication: 2021 May 01.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Computer Simulation*
Drug Interactions*
Cytochrome P-450 CYP3A Inhibitors/*pharmacokinetics
Orexin Receptor Antagonists/*pharmacokinetics
Pyridines/*pharmacokinetics
Pyrimidines/*pharmacokinetics
Humans ; Orexin Receptor Antagonists/administration & dosage ; Pyridines/administration & dosage ; Pyrimidines/administration & dosage

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Autorzy:: Landry I; Eisai Inc., Woodcliff Lake, NJ, USA.
Aluri J; Eisai Inc., Woodcliff Lake, NJ, USA.
Hall N; Eisai Inc., Woodcliff Lake, NJ, USA.
Filippov G; Eisai Inc., Woodcliff Lake, NJ, USA.
Dayal S; Eisai Ltd., Hatfield, United Kingdom.
Moline M; Eisai Inc., Woodcliff Lake, NJ, USA.
Reyderman L; Eisai Inc., Woodcliff Lake, NJ, USA.; Pokaż więcej
Źródło:: Pharmacology research & perspectives [Pharmacol Res Perspect] 2021 Apr; Vol. 9 (2), pp. e00734.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Orexin Receptor Antagonists/*pharmacokinetics
Pyridines/*pharmacokinetics
Pyrimidines/*pharmacokinetics
Renal Elimination/*physiology
Renal Insufficiency/*metabolism
Sleep Initiation and Maintenance Disorders/*drug therapy
Adolescent ; Adult ; Aged ; Area Under Curve ; Female ; Glomerular Filtration Rate/physiology ; Half-Life ; Humans ; Male ; Middle Aged ; Orexin Receptor Antagonists/administration & dosage ; Orexin Receptor Antagonists/adverse effects ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Renal Insufficiency/diagnosis ; Renal Insufficiency/physiopathology ; Severity of Illness Index ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Autorzy:: Dayal S; Eisai Ltd., Hatfield, United Kingdom.
Aluri J; Eisai Inc., Woodcliff Lake, NJ, USA.
Hall N; Eisai Inc., Woodcliff Lake, NJ, USA.
Filippov G; Eisai Inc., Woodcliff Lake, NJ, USA.
Moline M; Eisai Inc., Woodcliff Lake, NJ, USA.
Reyderman L; Eisai Inc., Woodcliff Lake, NJ, USA.
Landry I; Eisai Inc., Woodcliff Lake, NJ, USA.; Pokaż więcej
Źródło:: Pharmacology research & perspectives [Pharmacol Res Perspect] 2021 Apr; Vol. 9 (2), pp. e00758.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Hepatic Insufficiency/*metabolism
Hepatobiliary Elimination/*physiology
Pyridines/*pharmacokinetics
Pyrimidines/*pharmacokinetics
Sleep Aids, Pharmaceutical/*pharmacokinetics
Administration, Oral ; Adolescent ; Adult ; Aged ; Area Under Curve ; Female ; Healthy Volunteers ; Hepatic Insufficiency/diagnosis ; Hepatic Insufficiency/physiopathology ; Humans ; Male ; Middle Aged ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Severity of Illness Index ; Sleep Aids, Pharmaceutical/administration & dosage ; Sleep Aids, Pharmaceutical/adverse effects ; Sleep Initiation and Maintenance Disorders/drug therapy ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: An overview on synthetic and pharmaceutical prospective of pyrido[2,3-d]pyrimidines scaffold.
Autorzy:: Yadav P; Institute of Pharmaceutical Research, GLA University, Mathura, UP, India.
Shah K; Institute of Pharmaceutical Research, GLA University, Mathura, UP, India.; Pokaż więcej
Źródło:: Chemical biology & drug design [Chem Biol Drug Des] 2021 Mar; Vol. 97 (3), pp. 633-648. Date of Electronic Publication: 2020 Sep 29.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Anti-Infective Agents/*chemistry
Antineoplastic Agents/*chemistry
Hypoglycemic Agents/*chemistry
Pyridines/*chemistry
Pyrimidines/*chemistry
Anti-Infective Agents/chemical synthesis ; Anti-Infective Agents/pharmacology ; Anti-Inflammatory Agents/chemical synthesis ; Anti-Inflammatory Agents/chemistry ; Anti-Inflammatory Agents/metabolism ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/pharmacology ; Bacteria/drug effects ; Cell Survival/drug effects ; Humans ; Hypoglycemic Agents/metabolism ; Pyridines/chemical synthesis ; Pyridines/pharmacology ; Pyrimidines/chemical synthesis ; Pyrimidines/pharmacology ; Structure-Activity Relationship ; alpha-Amylases/antagonists & inhibitors ; alpha-Amylases/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults.
Autorzy:: Landry I; Eisai Inc, Woodcliff Lake, New Jersey, USA.
Nakai K; Eisai Co, Ltd, Koishikawa, Tokyo, Japan.
Ferry J; Eisai Inc, Woodcliff Lake, New Jersey, USA.
Aluri J; Eisai Inc, Woodcliff Lake, New Jersey, USA.
Hall N; Eisai Inc, Woodcliff Lake, New Jersey, USA.
Lalovic B; Eisai Inc, Woodcliff Lake, New Jersey, USA.
Moline ML; Eisai Inc, Woodcliff Lake, New Jersey, USA.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 Feb; Vol. 10 (2), pp. 153-165. Date of Electronic Publication: 2020 May 28.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Orexin Receptor Antagonists/*administration & dosage
Pyridines/*administration & dosage
Pyrimidines/*administration & dosage
Adult ; Age Factors ; Aged ; Asian People ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Half-Life ; Humans ; Male ; Middle Aged ; Orexin Receptor Antagonists/adverse effects ; Orexin Receptor Antagonists/pharmacokinetics ; Pyridines/adverse effects ; Pyridines/pharmacokinetics ; Pyrimidines/adverse effects ; Pyrimidines/pharmacokinetics ; Sex Factors ; White People

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexant.
Autorzy:: Landry I; Eisai Inc., Woodcliff Lake, NJ, USA.
Aluri J; Eisai Inc., Woodcliff Lake, NJ, USA.
Hall N; Eisai Inc., Woodcliff Lake, NJ, USA.
Kumar D; Eisai Inc., Woodcliff Lake, NJ, USA.
Dayal S; Eisai Ltd., Hatfield, United Kingdom.
Moline M; Eisai Inc., Woodcliff Lake, NJ, USA.
Reyderman L; Eisai Inc., Woodcliff Lake, NJ, USA.; Pokaż więcej
Źródło:: Pharmacology research & perspectives [Pharmacol Res Perspect] 2020 Dec; Vol. 8 (6), pp. e00678.
Typ publikacji:: Clinical Trial, Phase I; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Famotidine/*pharmacokinetics
Gastric Acid/*metabolism
Histamine H2 Antagonists/*pharmacokinetics
Orexin Receptor Antagonists/*pharmacokinetics
Pyridines/*pharmacokinetics
Pyrimidines/*pharmacokinetics
Adult ; Double-Blind Method ; Drug Interactions/physiology ; Famotidine/administration & dosage ; Female ; Histamine H2 Antagonists/administration & dosage ; Humans ; Male ; Orexin Receptor Antagonists/administration & dosage ; Pyridines/administration & dosage ; Pyrimidines/administration & dosage ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Synthesis, In Silico Prediction and In Vitro Evaluation of Antitumor Activities of Novel Pyrido[2,3- d ]pyrimidine, Xanthine and Lumazine Derivatives.
Autorzy:: El-Kalyoubi S; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Nasr City, Cairo 11651, Egypt.
Agili F; Chemistry Department, Faculty of Science (Female Section), Jazan University, Jazan 82621, Saudi Arabia.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2020 Nov 09; Vol. 25 (21). Date of Electronic Publication: 2020 Nov 09.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents/*chemical synthesis
Neoplasms/*drug therapy
Pteridines/*chemical synthesis
Pyridines/*chemical synthesis
Pyrimidines/*chemical synthesis
Xanthine/*chemical synthesis
A549 Cells ; Antineoplastic Agents/pharmacology ; Binding Sites ; Chemistry Techniques, Synthetic ; Cyclin-Dependent Kinase 2/chemistry ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Folic Acid/chemistry ; Humans ; Inhibitory Concentration 50 ; Janus Kinase 2/chemistry ; MCF-7 Cells ; Molecular Docking Simulation ; Proto-Oncogene Proteins c-bcl-2/chemistry ; Proto-Oncogene Proteins c-mdm2/chemistry ; Pteridines/pharmacology ; Pyridines/pharmacology ; Pyrimidines/pharmacology ; Tetrahydrofolate Dehydrogenase/chemistry ; Tumor Suppressor Protein p53/chemistry ; Xanthine/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys.
Autorzy:: Horita S; R&D Division Kyowa Kirin Co., Ltd. Sunto-gun Shizuoka Japan.; Department of Clinical Pharmaceutics School of Pharmaceutical Sciences University of Shizuoka Sunto-gun Shizuoka Japan.
Watanabe M; R&D Division Kyowa Kirin Co., Ltd. Sunto-gun Shizuoka Japan.
Katagiri M; R&D Division Kyowa Kirin Co., Ltd. Sunto-gun Shizuoka Japan.
Nakamura H; R&D Division Kyowa Kirin Co., Ltd. Sunto-gun Shizuoka Japan.
Haniuda H; Production Division Kyowa Kirin Co., Ltd. Sunto-gun Shizuoka Japan.
Nakazato T; Production Division Kyowa Kirin Co., Ltd. Sunto-gun Shizuoka Japan.
Kagawa Y; Department of Clinical Pharmaceutics School of Pharmaceutical Sciences University of Shizuoka Sunto-gun Shizuoka Japan.; Pokaż więcej
Źródło:: Pharmacology research & perspectives [Pharmacol Res Perspect] 2019 Nov 20; Vol. 7 (6), pp. e00545. Date of Electronic Publication: 2019 Nov 20 (Print Publication: 2019).
Typ publikacji:: Journal Article
MeSH Terms:: Angiogenesis Inhibitors/*pharmacology
Choroidal Neovascularization/*drug therapy
Macular Degeneration/*drug therapy
Phenylurea Compounds/*pharmacology
Pyridines/*pharmacology
Pyrimidines/*pharmacology
Sulfonamides/*pharmacology
Angiogenesis Inhibitors/therapeutic use ; Animals ; Choroidal Neovascularization/etiology ; Choroidal Neovascularization/pathology ; Crystallization ; Disease Models, Animal ; Drug Evaluation, Preclinical ; Eye/metabolism ; Eye/pathology ; Female ; Humans ; Indazoles ; Macaca fascicularis ; Macular Degeneration/etiology ; Macular Degeneration/pathology ; Male ; Nanoparticles/chemistry ; Nanoparticles/therapeutic use ; Ophthalmic Solutions/pharmacology ; Ophthalmic Solutions/therapeutic use ; Particle Size ; Phenylurea Compounds/chemistry ; Phenylurea Compounds/therapeutic use ; Pyridines/chemistry ; Pyridines/therapeutic use ; Pyrimidines/chemistry ; Pyrimidines/therapeutic use ; Rabbits ; Rats ; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors ; Species Specificity ; Sulfonamides/chemistry ; Sulfonamides/therapeutic use ; Vascular Endothelial Growth Factor A/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: F-NMR-based determination of the absorption, metabolism and excretion of the oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor leniolisib (CDZ173) in healthy volunteers.
Autorzy:: Pearson D; a Pharmacokinetic Sciences , Novartis Institutes for BioMedical Research , Novartis Pharma AG , Basel , Switzerland.
Garnier M; a Pharmacokinetic Sciences , Novartis Institutes for BioMedical Research , Novartis Pharma AG , Basel , Switzerland.
Luneau A; b Global Discovery Chemistry , Novartis Institutes for BioMedical Research , Novartis Pharma AG , Basel , Switzerland.
James AD; a Pharmacokinetic Sciences , Novartis Institutes for BioMedical Research , Novartis Pharma AG , Basel , Switzerland.
Walles M; a Pharmacokinetic Sciences , Novartis Institutes for BioMedical Research , Novartis Pharma AG , Basel , Switzerland.; Pokaż więcej
Źródło:: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2019 Aug; Vol. 49 (8), pp. 953-960. Date of Electronic Publication: 2018 Nov 29.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Absorption, Physiological*
Healthy Volunteers*
Magnetic Resonance Spectroscopy*
Phosphoinositide-3 Kinase Inhibitors*
Fluorine/*chemistry
Protein Kinase Inhibitors/*metabolism
Pyridines/*metabolism
Pyrimidines/*metabolism
Administration, Oral ; Adolescent ; Adult ; Feces ; Female ; Humans ; Male ; Metabolome ; Middle Aged ; Phosphatidylinositol 3-Kinases/metabolism ; Protein Kinase Inhibitors/blood ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/urine ; Pyridines/blood ; Pyridines/pharmacokinetics ; Pyridines/urine ; Pyrimidines/blood ; Pyrimidines/pharmacokinetics ; Pyrimidines/urine ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Pyridines"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język